Calcium acetate/magnesium carbonate

GrowGeneration Debuts Drip Hydro, a Complete Line of Liquid Fertilizer Blends Designed for Commercial Cultivators

Retrieved on: 
Tuesday, May 17, 2022
Other Consumer, Environment, Other Retail, Tobacco, Specialty, Consumer, Agriculture, Retail, Natural Resources, Online Retail, Plant, Multimedia, Lighting, Calcium acetate/magnesium carbonate, NASDAQ, McCormick–International Harvester Company Branch House, Industry, Nutrient, Taste, Hypochlorous acid, Fruit, Phosphorus, Oxygen, CEO, Coffee, Fertilizer, Calcium, Potassium, Flex

Drip Hydro was designed to improve quality, reduce costs, and drive consistency.

Key Points: 
  • Drip Hydro was designed to improve quality, reduce costs, and drive consistency.
  • Drip Hydro was formulated with the highest bio-available quality chelates and pharmaceutical grade salts.
  • Only after extensive testing, with some of the countrys best growers, were we ready to bring Drip to the market.
  • GrowGeneration creates and distributes many of its own proprietary private label brands from lighting and benching to nutrients and supplies.

Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

Retrieved on: 
Thursday, July 29, 2021
Chemistry, Physical sciences, Chemical elements, Detoxification, Dialysis, Membrane technology, Phosphorus, Calcium acetate/magnesium carbonate

To that end,the company intends to request a Type A meeting as soon as possible to discuss the CRL and determine potential paths forward for the approvalof tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis.

Key Points: 
  • To that end,the company intends to request a Type A meeting as soon as possible to discuss the CRL and determine potential paths forward for the approvalof tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis.
  • "We continue to believe tenapanor represents an important, first-in-class treatment option for patients with elevated phosphorus.
  • In our view, the serum phosphorus lowering data generated with tenapanor in all of our clinical studies is meaningful and clinically significant.
  • Ardelyx is developing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials.

Fresenius Medical Care's Frenova enrolls patients in initiative to build world's largest genomic registry targeting kidney disease

Retrieved on: 
Monday, January 11, 2021
Bad Homburg vor der Höhe, Fresenius, Societates Europaeae, Germany, Health care, Kidney diseases, Nephrology, Calcium acetate/magnesium carbonate

The renal-focused genomic registry represents a new business line within Frenova, which is based in Fresenius Medical Care's Global Medical Office.

Key Points: 
  • The renal-focused genomic registry represents a new business line within Frenova, which is based in Fresenius Medical Care's Global Medical Office.
  • Frenova's new genomic registry will contain genetic sequencing data from chronic kidney disease patients worldwide, which will be used by researchers to improve the understanding of kidney disease.
  • Frenova developed the registry after researchers identified the lack of a large-scale, renal-focused registry of genomic and clinical data as a major impediment to kidney disease research.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius Medical Care North America Partners with Livongo to Empower People with Chronic Kidney Disease

Retrieved on: 
Wednesday, October 7, 2020
Bad Homburg vor der Höhe, Fresenius, Germany, Medicine, Chronic kidney disease, Chronic condition, Calcium acetate/magnesium carbonate, Draft:Rice Powell

and MOUNTAIN VIEW, Calif., Oct. 7, 2020 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA) , the nation's leading renal care company, today announced an innovative partnership with Livongo Health, Inc., the leading Applied Health Signals company, to improve the lives and outcomes of people with late-stage chronic kidney disease (CKD).

Key Points: 
  • and MOUNTAIN VIEW, Calif., Oct. 7, 2020 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA) , the nation's leading renal care company, today announced an innovative partnership with Livongo Health, Inc., the leading Applied Health Signals company, to improve the lives and outcomes of people with late-stage chronic kidney disease (CKD).
  • "We are excited about our innovative partnership with Fresenius Medical Care North America to offer people living with chronic kidney disease a better care experience that is personalized to them and addresses all aspects of their health."
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.
  • Fresenius Health Partners (FHP), a division of Fresenius Medical Care North America (FMCNA), is committed to providing value based care services leveraging the comprehensive integrated network of FMCNA.

Fresenius Medical Care North America Prepares Dialysis Patients as Hurricane Laura Approaches Gulf Coast

Retrieved on: 
Wednesday, August 26, 2020
Bad Homburg vor der Höhe, Medicine, Private providers of NHS services, Clinical medicine, Membrane technology, Fresenius, Societates Europaeae, Health care, Dialysis, Draft:Rice Powell, Calcium acetate/magnesium carbonate

WALTHAM, Mass., Aug. 26, 2020 /PRNewswire/ --Fresenius Medical Care North America (FMCNA), the nation's leading provider of dialysis products and services, has activated its national disaster response team to ensure continuity of care as Hurricane Laura bears down on the Gulf Coast in Texas and Louisiana.

Key Points: 
  • WALTHAM, Mass., Aug. 26, 2020 /PRNewswire/ --Fresenius Medical Care North America (FMCNA), the nation's leading provider of dialysis products and services, has activated its national disaster response team to ensure continuity of care as Hurricane Laura bears down on the Gulf Coast in Texas and Louisiana.
  • Fresenius Kidney Care has been ensuring patients receive treatment prior to the storm by extending hours or moving patients to other clinics outside the evacuated areas.
  • Fresenius Kidney Care, a division of Fresenius Medical Care North America (FMCNA), provides dialysis treatment and support services to more than 200,000 people with kidney disease every year whether in their own homes or at more than 2,400 facilities nationwide.
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.

New Retrospective Two-Year Study Demonstrates Velphoro® Effectiveness

Retrieved on: 
Tuesday, March 31, 2020
Medicine, Phosphate binders, Clinical medicine, Chemistry, Sucroferric oxyhydroxide, Dialysis, Phosphorus, Chronic kidney disease, Kidney, Calcium acetate/magnesium carbonate, Vitamin and mineral supplementation for dialysis patients

"Previous real world studies have shown similar results with Velphoro, but lacked a control group," said first study author Dr. Daniel Coyne, Professor of Medicine, Washington University School of Medicine St Louis.

Key Points: 
  • "Previous real world studies have shown similar results with Velphoro, but lacked a control group," said first study author Dr. Daniel Coyne, Professor of Medicine, Washington University School of Medicine St Louis.
  • "This two-year analysis addresses that problem, and shows marked improvements with Velphoro that are not achieved using other phosphorus binders."
  • Velphoro is a non-calcium, chewable, iron-based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.
  • Velphoro has a high phosphate-binding capacity relative to equivalent doses of other commonly prescribed phosphate binders and the iron in Velphoro is minimally absorbed.

Fresenius Kidney Care Launches Online Kidney Care Community

Retrieved on: 
Monday, March 2, 2020
Medicine, Fresenius, Societates Europaeae, Health, Clinical medicine, Kidney, Renal dialysis, American Kidney Fund, Membrane technology, Calcium acetate/magnesium carbonate

WALTHAM, Mass., March 2, 2020 /PRNewswire/ --Fresenius Kidney Care, a division of Fresenius Medical Care North America (FMCNA) and the nation's leading network of dialysis facilities, has launched an online community to connect people impacted by kidney disease with peers around the country.

Key Points: 
  • WALTHAM, Mass., March 2, 2020 /PRNewswire/ --Fresenius Kidney Care, a division of Fresenius Medical Care North America (FMCNA) and the nation's leading network of dialysis facilities, has launched an online community to connect people impacted by kidney disease with peers around the country.
  • The Kidney Care Community is an online forum that provides information and inspiration for anyone impacted by chronic kidney disease (CKD), including people living with the disease and their families, friends, and caregivers.
  • "Having support from a community plays a critical role in a patient's care, providing a sense of connection among individuals living with kidney disease and their caregivers," said Mike Asselta, President of Fresenius Kidney Care.
  • Patients who already have a Fresenius Kidney Care PatientHub account can access the community directly by clicking the "Community" button in their PatientHub navigation menu.

Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis

Retrieved on: 
Tuesday, December 3, 2019
Medicine, Clinical medicine, Phosphate binders, Medical specialties, Detoxification, Dialysis, Membrane technology, Kidney diseases, Sucroferric oxyhydroxide, Renal dialysis, Calcium acetate/magnesium carbonate

Tenapanor is an investigational, first-in-class, phosphate absorption inhibitor being developed to treat hyperphosphatemia in patients with CKD on dialysis.

Key Points: 
  • Tenapanor is an investigational, first-in-class, phosphate absorption inhibitor being developed to treat hyperphosphatemia in patients with CKD on dialysis.
  • If approved, tenapanor will be the only non-binder treatment for the control of serum phosphorus in patients with CKD on dialysis.
  • Patients entering the study from the tenapanor arm with serum phosphorus levels in the normal range are followed with no medication changes.
  • In addition to the positive results of the PHREEDOM trial, the company previously reported results from its first Phase 3 monotherapy study with tenapanor in patients with CKD on dialysis, reporting that the primary endpoint was met (p=0.01).

Fresenius Medical Care North America Celebrates National Kidney Month with Donations of $195,000 to Support Educational Efforts and Home Dialysis Awareness

Retrieved on: 
Monday, March 4, 2019
Medicine, Clinical medicine, Health, Renal dialysis, Membrane technology, Home hemodialysis, Nephrology, Fresenius, Dialysis, Kidney, National Kidney Foundation Singapore, Calcium acetate/magnesium carbonate

National Kidney Month is celebrated every March and seeks to raise awareness about CKD, which impacts 1 in 7 adults in the United States.

Key Points: 
  • National Kidney Month is celebrated every March and seeks to raise awareness about CKD, which impacts 1 in 7 adults in the United States.
  • Recognizing that home dialysis offers patients greater independence, convenience and health, FMCNA is donating $65,000 to support the Medical Education Institute's (MEI) home dialysis awareness forum and other programming.
  • "We are proud to sponsor these organizations that provide important support and hope to people living with kidney disease."
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.

Velphoro® Doubles Percentage of Patients Reaching Target Serum Phosphorous Levels in New Study Published in Journal of Renal Nutrition

Retrieved on: 
Monday, January 28, 2019
Medicine, Clinical medicine, Medical specialties, Phosphate binders, RTT, Sucroferric oxyhydroxide, Hyperphosphatemia, Dialysis, Cardiovascular disease, Phosphorus, Calcium acetate/magnesium carbonate, Chronic kidney disease

High serum phosphorous levels, or hyperphospatemia, have previously been associated with increased cardiovascular disease and mortality.

Key Points: 
  • High serum phosphorous levels, or hyperphospatemia, have previously been associated with increased cardiovascular disease and mortality.
  • Oral phosphate binders, in combination with dialysis and dietary restriction, have been shown to effectively lower elevated phosphorus levels.
  • Sucroferric oxyhydroxide (Velphoro) is a non-calcium, chewable, iron-based phosphate binder indicated for the treatment of hyperphosphatemia in dialysis patients.
  • For more details of the study, read the manuscript online in the Journal of Renal Nutrition .